Last reviewed · How we verify
NCT06360289
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
trial testing Standard of Care in Hereditary Amyloidosis, Transthyretin-Related in 500 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | Alnylam Pharmaceuticals |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 25 April 2024 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- Standard of Care
Conditions studied
- Hereditary Amyloidosis, Transthyretin-Related — all drugs for Hereditary Amyloidosis, Transthyretin-Related →
- Asymptomatic Carrier State — all drugs for Asymptomatic Carrier State →
Sponsor
Alnylam Pharmaceuticals — full company profile →
Who can join
Eligibility, any sex, with Hereditary Amyloidosis, Transthyretin-Related or Asymptomatic Carrier State. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of TTR variants and symptomatic hATTR amyloidosis patients with polyneuropathy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06360289
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard of Care
Trials testing the same drug.
- NCT07337655 — Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker · Phase 2, PHASE3 · not yet recruiting
- NCT07018466 — Tele-Exercise for MERP · NA · not yet recruiting
- NCT06930768 — Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers · NA · not yet recruiting
- NCT06918548 — Evaluating the Efficacy of NeoThelium FT in the Treatment of Pressure Injuries · NA · not yet recruiting
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
Other recruiting trials for Hereditary Amyloidosis, Transthyretin-Related
Currently open trials in the same condition.
- NCT07080268 — Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis. · active not recruiting
- NCT07124377 — Phenotypic Manifestations of Hereditary ATTR Amyloidosis · recruiting
Other Alnylam Pharmaceuticals trials
Trials by the same sponsor.
- NCT07535606 — A Study to Evaluate ALN-4915 in Adult Healthy Volunteers · Phase 1 · recruiting
- NCT07463846 — A Study to Evaluate ALN-2232 in Participants With Obesity · Phase 1, PHASE2 · recruiting
- NCT07223203 — TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos · Phase 3 · recruiting
- NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
- NCT07358078 — DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06360289 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alnylam Pharmaceuticals
- Last refreshed: 24 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06360289.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing